Michael Hoelscher
19
3
3
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
17%
2 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
PanACEA - STEP2C -01
Role: lead
TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
Role: lead
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Role: lead
Increasing Neonatal HIV Test and Treat to Maximize the Long-Term Impact on Infant Health and Novel Infant Antiretroviral Treatment
Role: lead
Neonatal HIV Early Infant Diagnosis (EID) Versus Standard of Care EID- Long Term Impact on inFant hEalth (LIFE)
Role: lead
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
Role: lead
BTZ-043 Dose Evaluation in Combination and Selection
Role: lead
Early Risk Assessment in Household Contacts (≥10 Years) of TB Patients by New Diagnostic Tests in 3 African Countries
Role: lead
Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania.
Role: lead
PanACEA Sutezolid Dose-finding and Combination Evaluation
Role: lead
Rapid and Accurate Diagnosis of Paediatric TB (RaPaed-AIDA-TB)
Role: lead
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
Role: lead
A Single Ascending Dose Study of BTZ043
Role: lead
A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania
Role: lead
A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen
Role: lead
HIV Point-of-Care Test Evaluation in Infants
Role: lead
Establishment of a Clinical Trial Unit in Mavalane, Maputo, in Mozambique
Role: lead
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
Role: lead
Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB
Role: lead
All 19 trials loaded